As 2022 begins, the pandemic is still at the forefront of the healthcare industry. Recently, as COVID-19 case counts have risen dramatically around the world due to the highly infectious Omicron variant, new challenges are presenting:
- What is the best mitigation strategy?
- How do we protect the vulnerable?
- How and when should we test?
- Does this mean we are closer to a new "normal"?
Join A&M Healthcare Industry Group's Marthe Haverkamp, M.D., Ph.D, as she sits down with world-renowned virologist Ab Osterhaus, Ph.D., and vaccine expert Manon Cox, Ph.D., MBA, Chief Executive Officer and Co-Founder of NextWaveBio. They discuss the future of vaccines, the value of COVID-19 treatments, and the influence of Omicron on the pandemic: Is a relatively mild disease now a comparative advantage for the future?
Download the transcript
Subscribe to our Healthcare Industry Group Podcast:
The Most Undervalued Asset in Health Systems Isn’t a Building — It’s the Physician Enterprise
April 30, 2026
Health systems often look to buildings or rates for growth, but the strongest lever is frequently overlooked. This perspective reframes the physician enterprise as a scalable growth platform, and shows how leaders can unlock margin, resilience, and long-term value.
Access Reimagined: Meeting Evolving Workforce Expectations While Expanding Patient Reach
April 23, 2026
Redesign the system. Realign incentives. Reimagine access. Patrick J. Byrne, M.D., Chief of Cleveland Clinic's Integrated Surgical, and Lisa Ishii, M.D., M.H.S, SVP of Operations for Johns Hopkins Health System join A&M Healthcare Industry Group's Brian Giessler to share their vision for redesigning healthcare to deliver the right care at the right time.
LS: Next Growth Curve
April 22, 2026
Developed markets are facing structural headwinds, such as affordability constraints, pricing reform, as demographic saturation and slower volume growth are limiting expansion and resulting a moderating growth rate. In contrast, emerging markets are entering a phase of healthcare formalization and access expansion driven by rising chronic disease burden and government prioritization of pharmaceuticals
The Next Growth Curve: How Biopharma Can Win in Developing Markets
April 20, 2026
Developed markets are facing structural headwinds, such as affordability constraints, pricing reform, as demographic saturation and slower volume growth are limiting expansion and resulting a moderating growth rate. In contrast, emerging markets are entering a phase of healthcare formalization and access expansion driven by rising chronic disease burden and government prioritization of pharmaceuticals
